Cambrex Co. (NYSE:CBM) CEO Steven M. Klosk sold 55,000 shares of Cambrex stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total value of $3,646,500.00. Following the completion of the transaction, the chief executive officer now owns 138,328 shares of the company’s stock, valued at $9,171,146.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of CBM stock opened at $66.95 on Friday. Cambrex Co. has a 52 week low of $42.55 and a 52 week high of $67.85. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 20.99, a P/E/G ratio of 1.60 and a beta of 2.39.

Cambrex (NYSE:CBM) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.05. Cambrex had a return on equity of 22.32% and a net margin of 20.75%. The company had revenue of $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. During the same period in the previous year, the firm posted $0.76 earnings per share. Cambrex’s quarterly revenue was up 13.0% compared to the same quarter last year. equities research analysts predict that Cambrex Co. will post 2.82 EPS for the current year.

A number of equities analysts have commented on CBM shares. ValuEngine downgraded Cambrex from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 7th. Zacks Investment Research upgraded Cambrex from a “sell” rating to a “hold” rating in a research note on Wednesday, May 16th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $66.50.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Cambrex by 8.7% during the second quarter. BlackRock Inc. now owns 4,624,250 shares of the biotechnology company’s stock worth $241,849,000 after buying an additional 370,806 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Cambrex by 3.8% during the second quarter. Bank of New York Mellon Corp now owns 1,471,966 shares of the biotechnology company’s stock worth $76,982,000 after buying an additional 54,475 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Cambrex by 1.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,420,580 shares of the biotechnology company’s stock worth $74,295,000 after buying an additional 13,858 shares during the period. American Capital Management Inc. boosted its position in shares of Cambrex by 6.7% during the second quarter. American Capital Management Inc. now owns 720,476 shares of the biotechnology company’s stock worth $37,681,000 after buying an additional 45,312 shares during the period. Finally, Boston Partners boosted its position in shares of Cambrex by 3.2% during the second quarter. Boston Partners now owns 699,286 shares of the biotechnology company’s stock worth $36,572,000 after buying an additional 21,399 shares during the period.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

Further Reading: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.